Rexahn Pharmaceuticals, Inc. (NYSE:RNN)‘s stock had its “outperform” rating reiterated by research analysts at FBR & Co in a research report issued on Thursday. They presently have a $3.00 target price on the stock.

Separately, Zacks Investment Research upgraded Rexahn Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, June 21st.

Rexahn Pharmaceuticals (NYSE:RNN) opened at 0.18 on Thursday. The company’s market cap is $38.40 million. The firm’s 50-day moving average is $0.23 and its 200 day moving average is $0.27. Rexahn Pharmaceuticals has a 1-year low of $0.17 and a 1-year high of $0.52.

Rexahn Pharmaceuticals (NYSE:RNN) last released its earnings results on Monday, August 8th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.01. Analysts predict that Rexahn Pharmaceuticals will post ($0.07) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Rexahn Pharmaceuticals stock. Vanguard Group Inc. boosted its stake in shares of Rexahn Pharmaceuticals, Inc. (NYSE:RNN) by 1.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,904,097 shares of the company’s stock after buying an additional 49,761 shares during the period. Vanguard Group Inc. owned 2.30% of Rexahn Pharmaceuticals worth $1,232,000 as of its most recent SEC filing.

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

5 Day Chart for NYSE:RNN

Receive News & Stock Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.